Aclarubicin: Indication, Dosage, Side Effect, Precaution

This information is not country-specific. Please refer to the Indonesia prescribing information.

Generic Medicine Info

Indications and Dosage

Intravenous
Malignant blood disorders

Adult: Initially: 175-300 mg/m² given in divided doses over 3-7 consecutive days via IV infusion over 30-60 minutes. Maintenance: 25-100 mg/m² in a single infusion every 3-4 wk.

Contraindications

Pregnancy, lactation; CV disease.

Special Precautions

Myocardial irradiation and use of radiotherapy. Hepatic or renal impairment. Elderly.

Adverse Reactions

Nausea, vomiting, mucositis, irritant to tissue, sore mouth, bone-marrow suppression, hyperuricaemia. Alopoecia (rare).
Potentially Fatal: Cardiotoxicity (rare), myelosuppression in patients who received mitomycin or a nitrosourea, leucopenia.

Drug Interactions

Other cardiotoxic drugs e.g. daunorubicin or cyclophosphamide, live vaccines; decreases effects of digoxin, oral anticoagulants, phenytoin and suxamethonium.

Lab Interference

Elevated bilirubin level.

Action

Description:
Mechanism of Action: Aclarubicin is an anthracycline, a cytotoxic antibiotic, and inhibits RNA synthesis through intercalation.
Pharmacokinetics:
Distribution: Rapidly distributed into tissues after IV admin.
Metabolism: Extensively metabolised.
Excretion: Triphasic clearance. Terminal elimination half-life: About 3 hr. Excreted in urine mainly as metabolites.

MIMS Class

Cytotoxic Chemotherapy

Disclaimer: This information is independently developed by MIMS based on Aclarubicin from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by MIMS.com